Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with type 2 diabetes and ...

DexCom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, is ushering in the next era of transformative, ...

(COLORADO SPRINGS) — FOX21 News has learned alternative ways people are getting around the shortage of the medical device called the Dexcom, a glucose monitor for diabetes. Some diabetics are now ...

Lingo is Abbott’s over-the-counter continuous glucose monitor (CGM) for nondiabetic people. Withings users will also be able ...

This was the stock's second consecutive day of gains.

DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...

DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...

Oura and Dexcom are partnering on metabolic health — and they mean big business. Dexcom has invested $75 million into Oura to make the deal happen, valuing Oura at $5 billion. That works out to just a ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...